(i9) United States
(12) Patent Application Publication oo) Pub. No.: US 2006/0258698 Al
Mudumba et al. (43) Pub. Date: Nov. 16,2006
(54) LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
(76) Inventors: Sreenivasu Mudumba, Union City, CA
(US); Philippe JM Dor, Cupertino, CA
(US); Thierry Nivaggioli, Atherton, CA
(US); David A. Weber, Danville, CA
(US); Sidiq Farooq, Newark, CA (US)
MORRISON & FOERSTER LLP
755 PAGE MILL RD
PALO ALTO, CA 94304-1018 (US)
(21) Appl. No.: 11/351,761
Related U.S. Application Data
(60) Provisional application No. 60/664,306, filed on Mar. 21, 2005. Provisional application No. 60/664,040, filed on Mar. 21, 2005. Provisional application No. 60/651,790, filed on Feb. 9, 2005.
(51) Int. CI.
A61K 31/4745 (2006.01)
(52) U.S. CI 514/291
Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age-related macular degeneration in a subject. The liquid formulations may comprise rapamycin or other therapeutic agents.